Belkin Re-introduces InvisiGlass: Reliable Screen Protection, Now Made With Recycled Glass
9.9.2024 22:38:00 CEST | Business Wire | Press release
The new screen protectors incorporate an impressive 60% post-industrial recycled (PIR) materials1
Belkin, a leading consumer electronics brand for 40 years, today announced its reimagined InvisiGlass screen protection collection, made with certified recycled glass. The InvisiGlass screen protection collection is now available on belkin.com for iPhone 16, iPhone 16 Plus, iPhone 16 Pro, and iPhone 16 Pro Max.
Belkin InvisiGlass is made with glass materials that are collected and recycled during the manufacturing process, certified by the Global Recycled Standard (GRS), and thoroughly tested to ensure the premium quality, durability, reliability and clarity that the brand name is known for.
Fortified with ion-exchange technology, InvisiGlass screen protectors are 62%2 more durable than tempered glass screen protectors without adding thickness or weight to provide best-in-class protection while maintaining the device’s natural look and feel.
The ScreenForce™ InvisiGlass collection includes:
- InvisiGlass – $29.99 USD – the new InvisiGlass is an upgrade to the original InvisiGlass Ultra material introduced in 2017. The new version is enhanced with recycled glass while still smooth to the touch and ultra-thin, preserving touchscreen sensitivity.
- InvisiGlass Blue Light Filter – $34.99 USD – incorporates industry-leading blue light reduction technology by Eyesafe to filter out 60% of blue light3. It is designed to support eye comfort for more enjoyable screen time, whether working, reading, or streaming.
- InvisiGlass Privacy – $34.99 USD – engineered with an added privacy filter to keep emails, webpages, texts and photos protected from prying eyes. It is the ideal solution for working on sensitive documents, banking online, or simply browsing the web or social media.
Belkin InvisiGlass Screen Protectors come in 100% recycled packaging4 using paper certified by the Forest Stewardship Council. The package contains a cleaning cloth, dust removal sticker to prevent air bubbles, and patented Easy Align tray for flawless alignment and fool-proof application.
For more information on Belkin InvisiGlass, see here: www.belkin.com/screenforce/sustainability
Pricing and Availability
The Belkin InvisiGlass Screen Protector collection for the new iPhone 16 lineup is available on belkin.com today for $29.99 – $34.99 USD and coming soon to major retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
_________________________
1 Glass is made with a minimum of 60% post-industrial recycled glass and has been certified through GRS.
2 Based on internal tests, screen protectors can withstand up to 62% more force on average compared to conventional tempered glass screen protectors.
3 435-440 nm
4 Recycled plastic components include Easy Align tray, support tray, top protective film, and protective bags.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909753989/en/
Contacts
Media Contact
Media Contact
Jen Wei
VP of Global Communications and Corporate Development
comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom